Biotech | August 14, 2021
Bharat Biotech’s first nasal vaccine gets approval for Phase 2 trials
This is the first of its kind vaccine for Covid 19 to get the go-ahead
This is the first of its kind vaccine for Covid 19 to get the go-ahead
It falls under the Department of Biotechnology - Mission Covid Suraksha Project for augmenting manufacturing capacity for Covaxin
Substantial reduction in losses
The company is eligible for 12 months exclusivity from launch
The American Association for Clinical Chemistry (AACC); the American Society for Clinical Pathology (ASCP); the American Society of Hematology (ASH); and the International Myeloma Working Group (IMWG), collaborate to develop the guideline
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Subscribe To Our Newsletter & Stay Updated
